PACAP deficiency as a model of aging

D. Reglodi, T. Atlasz, E. Szabo, A. Jungling, A. Tamás, T. Juhasz, B. D. Fulop, A. Bardosi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Dysregulation of neuropeptides may play an important role in aging-induced impairments. In the long list of neuropeptides, pituitary adenylate cyclase–activating polypeptide (PACAP) represents a highly effective cytoprotective peptide that provides an endogenous control against a variety of tissue-damaging stimuli. PACAP has neuro- and general cytoprotective effects due to anti-apoptotic, anti-inflammatory, and antioxidant actions. As PACAP is also a part of the endogenous protective machinery, it can be hypothesized that the decreased protective effects in lack of endogenous PACAP would accelerate age-related degeneration and PACAP knockout mice would display age-related degenerative signs earlier. Recent results support this hypothesis showing that PACAP deficiency mimics aspects of age-related pathophysiological changes including increased neuronal vulnerability and systemic degeneration accompanied by increased apoptosis, oxidative stress, and inflammation. Decrease in PACAP expression has been shown in different species from invertebrates to humans. PACAP-deficient mice display numerous pathological alterations mimicking early aging, such as retinal changes, corneal keratinization and blurring, and systemic amyloidosis. In the present review, we summarize these findings and propose that PACAP deficiency could be a good model of premature aging.

Original languageEnglish
JournalGeroScience
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Peptides
Neuropeptides
Premature Aging
Amyloidosis
Invertebrates
Knockout Mice
Oxidative Stress
Anti-Inflammatory Agents
Antioxidants
Apoptosis
Inflammation

Keywords

  • Aging
  • Amyloidosis
  • Apoptosis
  • Degeneration
  • PACAP

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Reglodi, D., Atlasz, T., Szabo, E., Jungling, A., Tamás, A., Juhasz, T., ... Bardosi, A. (Accepted/In press). PACAP deficiency as a model of aging. GeroScience. https://doi.org/10.1007/s11357-018-0045-8

PACAP deficiency as a model of aging. / Reglodi, D.; Atlasz, T.; Szabo, E.; Jungling, A.; Tamás, A.; Juhasz, T.; Fulop, B. D.; Bardosi, A.

In: GeroScience, 01.01.2018.

Research output: Contribution to journalArticle

Reglodi, D, Atlasz, T, Szabo, E, Jungling, A, Tamás, A, Juhasz, T, Fulop, BD & Bardosi, A 2018, 'PACAP deficiency as a model of aging', GeroScience. https://doi.org/10.1007/s11357-018-0045-8
Reglodi, D. ; Atlasz, T. ; Szabo, E. ; Jungling, A. ; Tamás, A. ; Juhasz, T. ; Fulop, B. D. ; Bardosi, A. / PACAP deficiency as a model of aging. In: GeroScience. 2018.
@article{5125abcd3b874e1596a2e56975c9b037,
title = "PACAP deficiency as a model of aging",
abstract = "Dysregulation of neuropeptides may play an important role in aging-induced impairments. In the long list of neuropeptides, pituitary adenylate cyclase–activating polypeptide (PACAP) represents a highly effective cytoprotective peptide that provides an endogenous control against a variety of tissue-damaging stimuli. PACAP has neuro- and general cytoprotective effects due to anti-apoptotic, anti-inflammatory, and antioxidant actions. As PACAP is also a part of the endogenous protective machinery, it can be hypothesized that the decreased protective effects in lack of endogenous PACAP would accelerate age-related degeneration and PACAP knockout mice would display age-related degenerative signs earlier. Recent results support this hypothesis showing that PACAP deficiency mimics aspects of age-related pathophysiological changes including increased neuronal vulnerability and systemic degeneration accompanied by increased apoptosis, oxidative stress, and inflammation. Decrease in PACAP expression has been shown in different species from invertebrates to humans. PACAP-deficient mice display numerous pathological alterations mimicking early aging, such as retinal changes, corneal keratinization and blurring, and systemic amyloidosis. In the present review, we summarize these findings and propose that PACAP deficiency could be a good model of premature aging.",
keywords = "Aging, Amyloidosis, Apoptosis, Degeneration, PACAP",
author = "D. Reglodi and T. Atlasz and E. Szabo and A. Jungling and A. Tam{\'a}s and T. Juhasz and Fulop, {B. D.} and A. Bardosi",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11357-018-0045-8",
language = "English",
journal = "GeroScience",
issn = "2509-2715",
publisher = "Springer International Publishing AG",

}

TY - JOUR

T1 - PACAP deficiency as a model of aging

AU - Reglodi, D.

AU - Atlasz, T.

AU - Szabo, E.

AU - Jungling, A.

AU - Tamás, A.

AU - Juhasz, T.

AU - Fulop, B. D.

AU - Bardosi, A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Dysregulation of neuropeptides may play an important role in aging-induced impairments. In the long list of neuropeptides, pituitary adenylate cyclase–activating polypeptide (PACAP) represents a highly effective cytoprotective peptide that provides an endogenous control against a variety of tissue-damaging stimuli. PACAP has neuro- and general cytoprotective effects due to anti-apoptotic, anti-inflammatory, and antioxidant actions. As PACAP is also a part of the endogenous protective machinery, it can be hypothesized that the decreased protective effects in lack of endogenous PACAP would accelerate age-related degeneration and PACAP knockout mice would display age-related degenerative signs earlier. Recent results support this hypothesis showing that PACAP deficiency mimics aspects of age-related pathophysiological changes including increased neuronal vulnerability and systemic degeneration accompanied by increased apoptosis, oxidative stress, and inflammation. Decrease in PACAP expression has been shown in different species from invertebrates to humans. PACAP-deficient mice display numerous pathological alterations mimicking early aging, such as retinal changes, corneal keratinization and blurring, and systemic amyloidosis. In the present review, we summarize these findings and propose that PACAP deficiency could be a good model of premature aging.

AB - Dysregulation of neuropeptides may play an important role in aging-induced impairments. In the long list of neuropeptides, pituitary adenylate cyclase–activating polypeptide (PACAP) represents a highly effective cytoprotective peptide that provides an endogenous control against a variety of tissue-damaging stimuli. PACAP has neuro- and general cytoprotective effects due to anti-apoptotic, anti-inflammatory, and antioxidant actions. As PACAP is also a part of the endogenous protective machinery, it can be hypothesized that the decreased protective effects in lack of endogenous PACAP would accelerate age-related degeneration and PACAP knockout mice would display age-related degenerative signs earlier. Recent results support this hypothesis showing that PACAP deficiency mimics aspects of age-related pathophysiological changes including increased neuronal vulnerability and systemic degeneration accompanied by increased apoptosis, oxidative stress, and inflammation. Decrease in PACAP expression has been shown in different species from invertebrates to humans. PACAP-deficient mice display numerous pathological alterations mimicking early aging, such as retinal changes, corneal keratinization and blurring, and systemic amyloidosis. In the present review, we summarize these findings and propose that PACAP deficiency could be a good model of premature aging.

KW - Aging

KW - Amyloidosis

KW - Apoptosis

KW - Degeneration

KW - PACAP

UR - http://www.scopus.com/inward/record.url?scp=85055724927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055724927&partnerID=8YFLogxK

U2 - 10.1007/s11357-018-0045-8

DO - 10.1007/s11357-018-0045-8

M3 - Article

JO - GeroScience

JF - GeroScience

SN - 2509-2715

ER -